Skip to content
Screener

Harmony Biosciences Holdings, Inc. HRMY Total Equity

Total Equity at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$4.53B+8.6%
Alkermes logo
AlkermesALKS
$1.81B+11.3%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$54.59M+2.6%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$394.88M+12.8%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$33.02M+129%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$1.31B+58.9%

Other financials

Income statement

See full
Revenue$215.4M+16.6%
Gross profit$170.9M+11.9%
Operating income$37.3M-33.7%
Net income$32.5M-28.7%
EPS (diluted)$0.55-29.5%

Balance sheet

See full
Cash & equivalents$589.4M+20.5%
Total debt$164.6M-7.2%
Total assets$1.3B+20.5%

Cash flow

See full
Operating cash flow$27.8M-18.3%
CapEx$107.0K-79.1%
Free cash flow$126.0M+67.9%

Valuation

See full
Market cap$2.26B+13.1%
Enterprise value$1.83B+12.9%
P/E15.5×+4.5×
P/S2.5×-0.1×

Profitability

See full
Gross margin76.5%-1.8pp
Operating margin21.1%-5.1pp
Net margin16.2%-4.3pp
FCF margin40.1%+9.5pp

Returns & leverage

See full
Return on equity17.9%-6.9pp
Debt / equity0.2×-0.1×
Current ratio3.6×-0.1×

Where this comes from

Reported directly by Harmony Biosciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Harmony Biosciences Holdings, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 8:16 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-056720
Line itemMarch 31, 2026December 31, 2025
COMMITMENTS AND CONTINGENCIES (Note 13)
STOCKHOLDERS’ EQUITY:
Common stock—$0.00001 par value; 500,000,000 shares authorized at March 31, 2026 and December 31, 2025, respectively; 57,867,389 and 57,726,170 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively11
Additional paid in capital717,370708,968
Accumulated other comprehensive (loss) income(413)346
Retained earnings193,391160,903
TOTAL STOCKHOLDERS’ EQUITY910,349870,218
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$1,271,824$1,271,631

Item 1. Financial Statements

FAQ

What is Harmony Biosciences Holdings, Inc.'s total equity?
Harmony Biosciences Holdings, Inc. (HRMY) reported total equity of $910.35M in Q1 2026.
How has Harmony Biosciences Holdings, Inc.'s total equity changed year-over-year?
Harmony Biosciences Holdings, Inc.'s total equity increased by 26.3% year-over-year, from $720.53M to $910.35M.
What is the long-term trend for Harmony Biosciences Holdings, Inc.'s total equity?
Over 5 years (2020 to 2025), Harmony Biosciences Holdings, Inc.'s total equity has grown at a 55.0% compound annual growth rate (CAGR), from $97.18M to $870.22M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Harmony Biosciences Holdings, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude